Tilray (TLRY) Stock Price, News & Analysis

-0.14 (-6.60%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
52.42 million shs
Average Volume
36.60 million shs
Market Capitalization
$1.53 billion
P/E Ratio
Dividend Yield
Price Target

Tilray MarketRank™ Stock Analysis

Analyst Rating
2.25 Rating Score
36.8% Upside
$2.71 Price Target
Short Interest
14.91% of Shares Sold Short
Dividend Strength
News Sentiment
0.53mentions of Tilray in the last 14 days
Based on 24 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.30) to ($0.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.66 out of 5 stars

Consumer Staples Sector

111th out of 132 stocks

Medicinals & Botanicals Industry

6th out of 11 stocks

TLRY stock logo

About Tilray Stock (NASDAQ:TLRY)

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Nanaimo, Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

TLRY Stock Price History

TLRY Stock News Headlines

Cannabis Stocks: Game-Changing Catalyst for the Sector?
Cannabis stocks reignited Tuesday afternoon after the U.S. Department of Justice announced that it would move to reclassify marijuana as a less dangerous drug. As a result of the breaking news, several leading cannabis stocks, like Tilray NASDAQ: TLRY, Aurora Cannabis NASDAQ: ACB, and Canopy Growth NASDAQ: CGC experienced notable upticks in volume and price, posting impressive double-digit intraday gains before pulling back on Wednesday.
Cannabis Stocks: Game-Changing Catalyst for the Sector?
Cannabis stock surged higher on Tuesday following reports that the DEA will approve rescheduling of marijuana as a lower-risk drug.
The 3 Most Undervalued Penny Stocks to Buy in May 2024
3 Must-Buy Meme Stocks When Prices Plunge
3 Cheap Cannabis Stocks to Buy Now: May 2024
Tilray (NASDAQ:TLRY) Stock Price Down 0.4%
The 3 Best Cannabis Stocks to Buy in May 2024
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
See More Headlines
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$627.12 million
Cash Flow
$0.00 per share
Book Value
$5.07 per share


Free Float
Market Cap
$1.53 billion
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

TLRY Stock Analysis - Frequently Asked Questions

Should I buy or sell Tilray stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings
or view top-rated stocks.

What is Tilray's stock price target for 2024?

4 equities research analysts have issued 12-month price objectives for Tilray's stock. Their TLRY share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.71 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for TLRY
or view top-rated stocks among Wall Street analysts.

How have TLRY shares performed in 2024?

Tilray's stock was trading at $2.30 at the beginning of 2024. Since then, TLRY stock has decreased by 13.9% and is now trading at $1.98.
View the best growth stocks for 2024 here

When is Tilray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our TLRY earnings forecast

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings data on Monday, April, 10th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $1.84. The business had revenue of $145.59 million for the quarter, compared to analyst estimates of $150.13 million. Tilray had a negative trailing twelve-month return on equity of 2.68% and a negative net margin of 43.98%. The company's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 EPS.

What ETFs hold Tilray's stock?
What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).

When did Tilray IPO?

Tilray (TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Tidal Investments LLC (1.38%), Vanguard Group Inc. (0.46%), Mirae Asset Global Investments Co. Ltd. (0.35%), Swiss National Bank (0.19%), Simplex Trading LLC (0.00%) and California State Teachers Retirement System (0.09%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Denise M Faltischek, Irwin D Simon, James R Meiers and Mitchell Gendel.
View institutional ownership trends

How do I buy shares of Tilray?

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLRY) was last updated on 5/19/2024 by Staff

From Our Partners